The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Maybe if the health insurance and pharmaceutical industries weren’t such grifters, people wouldn’t have to turn to alternatives.” ...

March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...

The FDA has issued 30 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs. Regulators say some companies im ...

Part of "a new era of enforcement," says FDA chief ...

1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026.

Related: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs Being Mass-Marketed by Companies — Including Hims & Hers and Other Compounding Pharmacies March 4, 2026 - The U.S. Food and ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial with injectable compound and a syringe. - Anna Hoychuk // Shutterstock Compounded semaglutide is a medication that’s custom ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.